Lisa Graver is an experienced pharmaceutical executive with more than 25 years of leadership experience across the specialized generics, biosimilars, and branded sectors. She has held senior executive roles spanning commercial, operational and strategic functions and most recently served as Chief Executive Officer of Alvogen, overseeing the company through its growth and subsequent acquisition by Lotus Pharmaceutical Co.

Ms. Graver served as a member of the Alvotech Board from 2022 up to her appointment as CEO in 2026 and brings deep familiarity with the company’s strategy and operations. She holds an Honors BSc in Biology from Lakehead University and a law degree from Case Western Reserve University School of Law.